- Home
- UAMY vs OCGN Comparison
UAMY vs OCGN Comparison
Compare UAMY & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAMY
- OCGN
- Stock Information
- Founded
- UAMY 1968
- OCGN 2013
- Country
- UAMY United States
- OCGN United States
- Employees
- UAMY N/A
- OCGN N/A
- Industry
- UAMY Metal Fabrications
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UAMY Industrials
- OCGN Health Care
- Exchange
- UAMY Nasdaq
- OCGN Nasdaq
- Market Cap
- UAMY 206.0M
- OCGN 229.2M
- IPO Year
- UAMY N/A
- OCGN N/A
- Fundamental
- Price
- UAMY $1.57
- OCGN $0.68
- Analyst Decision
- UAMY Strong Buy
- OCGN Strong Buy
- Analyst Count
- UAMY 2
- OCGN 3
- Target Price
- UAMY $1.75
- OCGN $6.00
- AVG Volume (30 Days)
- UAMY 2.2M
- OCGN 3.5M
- Earning Date
- UAMY 04-11-2025
- OCGN 03-05-2025
- Dividend Yield
- UAMY N/A
- OCGN N/A
- EPS Growth
- UAMY N/A
- OCGN N/A
- EPS
- UAMY N/A
- OCGN N/A
- Revenue
- UAMY $10,219,826.00
- OCGN $4,700,000.00
- Revenue This Year
- UAMY $62.73
- OCGN N/A
- Revenue Next Year
- UAMY $194.39
- OCGN N/A
- P/E Ratio
- UAMY N/A
- OCGN N/A
- Revenue Growth
- UAMY 28.40
- OCGN N/A
- 52 Week Low
- UAMY $0.17
- OCGN $0.64
- 52 Week High
- UAMY $2.35
- OCGN $2.11
- Technical
- Relative Strength Index (RSI)
- UAMY 42.03
- OCGN 40.75
- Support Level
- UAMY $1.79
- OCGN $0.67
- Resistance Level
- UAMY $2.09
- OCGN $0.76
- Average True Range (ATR)
- UAMY 0.15
- OCGN 0.04
- MACD
- UAMY -0.04
- OCGN 0.00
- Stochastic Oscillator
- UAMY 3.70
- OCGN 28.57
About UAMY United States Antimony Corporation
United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company. It has four operating segments: United States Antimony, Mexican antimony, zeolite, and Precious metals. Its products and services include antimony; silver; gold; zeolite products; and storage, handling, & packaging services. The company's geographical segments are the United States, Canada, and Mexico, of which the vast majority of its revenue comes from the United States.
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").